Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

M1 Kliniken focuses on beauty after pharma sale and shows rising profitability

M1 Kliniken is concentrating fully on the profitable beauty segment after selling its pharma business, which grew by 11% in H1 to €56.9m. Segment EBIT rose 23.8% to €18.6m and the margin climbed to 32.7%; management targets 2029 revenue of €200–300m and an EBIT margin of at least 20%. With a major shareholder (MPH Health Care) holding over 66% and low free float, M1 Kliniken is seen as an attractive takeover or going-private candidate; a price target of €26.50 (about 31% upside) is cited. » More on finanzen.net
M1 Kliniken posts double-digit revenue and margin growth in beauty business

Adjusted figures show M1 Kliniken’s core business increased revenue in H1 2026 by 11% to €56.9m and improved EBIT by almost 24% to €18.6m; in Q2 revenue growth accelerated to around 16%. The prior sharp decline in group metrics resulted from the deconsolidation and sale of wholesale subsidiary Haemato Pharm. Management confirms a mid-term target of €200–300m revenue by 2029 with an EBIT margin of at least 20% (H1 margin: >32%). Analysts raised the price target, leaving upside of almost 50%; the P/E for 2026 is expected to be below 14. » More on finanzen.net
M1 Kliniken impresses with robust growth and a strong dividend increase

M1 Kliniken's stock has risen in recent months to close to its all-time high. The Düsseldorf-based company reports robust growth and surprised with a significantly increased dividend. If the ambitious forecasts are met, the authors see further upside potential for the share price. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, M1 Kliniken has already paid €1.20 in dividends. The last payout was in July.

Financials

In the last quarter, M1 Kliniken had revenue of €76.6M and net profit of €9.72M

(EUR)	June 2026	YoY
Revenue	76.6M	-
Gross profit	23.6M	-
Net profit	9.72M	-
EBITDA	17.68M	-

Fundamentals

Metric	Value
Market capitalization	€359.6M
Number of shares	18.56M
52-week high/low	€21.70 - €13.62
Dividend yield	6.17%
Dividends TTM	€1.20
Beta	1.01
P/E ratio	17.78
PEG ratio	1.31
P/B ratio	2.92
P/S ratio	1.40

Company profile

M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company operates in two segments, Beauty and Trade. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine and cosmetic dermatology, as well as trades in pharmaceutical, biosimilars, and other medical products and devices in the areas of oncology, HIV, rheumatism, neurology, cardiovascular diseases, and narcotics. The company also engages in the acquisition, management, and sale of real estate, primarily in the health care sector. It offers its products to doctors, pharmacies, and wholesalers under the M1 Select brand. The company operates a network of outpatient specialist centers; and a specialized surgical clinic center, as well as 46 specialist centers under the M1 Med Beauty brand. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.

Name	M1 Kliniken
CEO	Attila Strauss
Headquarters	Berlin, be Germany
Website	m1-kliniken.de
Sector	Health Care
Industry	Health Care Providers & Services
IPO	09/14/2015
Employees	280